Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Shares Bought by Ladenburg Thalmann Financial Services Inc.

Ladenburg Thalmann Financial Services Inc. raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 56.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,651 shares of the specialty pharmaceutical company’s stock after purchasing an additional 595 shares during the quarter. Ladenburg Thalmann Financial Services Inc.’s holdings in Jazz Pharmaceuticals were worth $233,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. MAI Capital Management increased its stake in Jazz Pharmaceuticals by 2.2% in the second quarter. MAI Capital Management now owns 4,364 shares of the specialty pharmaceutical company’s stock valued at $622,000 after purchasing an additional 96 shares during the period. Eaton Vance Management increased its stake in Jazz Pharmaceuticals by 4.8% in the second quarter. Eaton Vance Management now owns 154,860 shares of the specialty pharmaceutical company’s stock valued at $22,077,000 after purchasing an additional 7,033 shares during the period. United Services Automobile Association increased its stake in Jazz Pharmaceuticals by 178.3% in the second quarter. United Services Automobile Association now owns 38,725 shares of the specialty pharmaceutical company’s stock valued at $5,521,000 after purchasing an additional 24,808 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new position in Jazz Pharmaceuticals in the second quarter valued at $425,000. Finally, Worldquant Millennium Advisors LLC increased its stake in Jazz Pharmaceuticals by 14.3% in the second quarter. Worldquant Millennium Advisors LLC now owns 12,087 shares of the specialty pharmaceutical company’s stock valued at $1,723,000 after purchasing an additional 1,516 shares during the period. Institutional investors own 87.54% of the company’s stock.

A number of research firms have commented on JAZZ. Evercore ISI restated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, August 12th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $150.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, October 14th. BidaskClub downgraded shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, October 11th. TheStreet raised shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Wednesday, July 24th. Finally, BMO Capital Markets set a $208.00 target price on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, July 3rd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $167.20.

In related news, SVP Paul Treacy sold 4,371 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $137.40, for a total transaction of $600,575.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Catherine A. Sohn sold 726 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $135.65, for a total transaction of $98,481.90. Following the sale, the director now directly owns 9,574 shares in the company, valued at approximately $1,298,713.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,597 shares of company stock worth $764,057. 4.30% of the stock is owned by insiders.

Shares of NASDAQ:JAZZ opened at $119.65 on Friday. The company has a market cap of $6.86 billion, a price-to-earnings ratio of 9.78, a PEG ratio of 1.49 and a beta of 1.11. The firm’s 50-day simple moving average is $126.27 and its 200-day simple moving average is $133.10. The company has a quick ratio of 3.52, a current ratio of 3.71 and a debt-to-equity ratio of 0.58. Jazz Pharmaceuticals PLC has a fifty-two week low of $113.52 and a fifty-two week high of $165.66.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.16 by $0.49. The firm had revenue of $534.13 million for the quarter, compared to the consensus estimate of $507.23 million. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The firm’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.49 earnings per share. On average, research analysts forecast that Jazz Pharmaceuticals PLC will post 13.44 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: How a Strangle Strategy is different from a Straddle Strategy

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.